How Yale, the FDA, and Merck Lied About Molnupiravir’s Inferiority to Ivermectin

ByPrimary Researcher

Executive Summary

  • The health authorities have done their best to stigmatize the use of Ivermectin and promote far less effective and more risky drugs.
  • One of these is Molnupiravir.

Introduction

Ivermectin is a drug that is highly effective against multiple ailments. However, because this drug is now generic, Merck and the health authorities have decided to denigrate the drug. While Merck was telling the public that therapeutics like Ivermectin was ineffective against covid, it was busy creating a substitute that was on-patent. This drug is called Molnupiravir. Ivermectin works for many ailments and is highly supportive of general health. However, this article will cover how pharmaceutical companies, health authorities, and establishment media they control push the public away from proven generic drugs to far more risky and less effective on-patent drugs.

Go to top

Reviewing the Yale Medicine Website

It is very difficult to get quality information from medical schools’ websites, and they are entirely funded by pharmaceutical companies and ultimately in the pharmaceutical matrix. When reading the websites of medical schools, it is profoundly concerning what type of advice one will obtain from an MD who was indoctrinated in a pharma-run medical school, and the Yale Medical School is par for the course.

Yale Medical School on Emergency Use Authorization

Since this story about Merck’s molnupiravir was originally published, the Food and Drug Administration has provided emergency use authorizations for pills from both Merck and Pfizer. Scientists continue to study the real-world effectiveness of both. – Yale Medical School

Emergency Use Authorization (EUA) is a way the FDA provides approval without sufficient evidence that the drug works. This is how the covid vaccines, which later were demonstrated not to work, were approved. I covered this in the article How Emergency Use Authorization For The Covid Vaccines Is A Get Out Of Jail Free Card For the FDA. Curiously, Molnupiravir was designed to be used by people who are vaccinated — which brings up the question, if the vaccines worked, why is therapeutic required in the first place? This is addressed in the following quote.

“The vaccine is our first-line tool for preventing hospitalization, and I’m a little concerned that the attention on molnupiravir will draw attention away from vaccination,” says Dr. Meyer. “Some people might say, ‘I’m not getting vaccinated because I’ll have access to these medications’—to this pill or to remdesivir or other treatments. But you can’t trade one for the other. If you haven’t done so already, the most important thing is still to get the vaccine.”

If the vaccines were effective, there would be no need for Molnupiravir or other therapeutic. So Yale Medical School and the overall health establishment are saying inconsistent things. The pharmaceutical companies brought out ineffective and dangerous vaccines and have come up with excuses as to why they should still be used. This EUA given to Molnupiravir was entirely unnecessary as Ivermectin is a proven and superior therapeutic (along with addressing vitamin deficiencies like Vitamin D and K, etc..). Still, as a front end for pharmaceutical companies, the FDA could not have a generic drug become popular as a therapeutic for covid.

More Ineffective and On Patent Therapeutics?

Pfizer submitted its application in November for a medication called Paxlovid.

Since this time, Paxlovid has proven to be utterly ineffective against covid. But Pfizer wanted to jump on the therapeutic money train, and they could get virtually anything approved or given a EUA by the FDA.

Yale MD Lies Multiple Ways About Various Drugs

This following quote needs its laugh track.

“It certainly has the potential to be a really important advance,” said Albert Shaw, MD, PhD, a Yale Medicine infectious diseases specialist, when the Merck application was submitted. “Other COVID-19 treatments, such as remdesivir or monoclonal antibodies against the SARS-CoV-2 virus causing COVID-19, are given intravenously. This is a pill your physician could write a prescription for, that you could pick up in a drugstore.” – Yale Medical School

It has now been tested on human guinea pigs with its EUA, and both of these therapeutics are ineffective.